城市新业态(共7份)
新经济消费崛起,点我速看
-
艾媒报告 |2019中国按摩椅产业及共享按摩椅市场分析报告
本报告研究涉及企业/品牌/案例:京东,傲胜,荣泰健康,奥佳华,V3 group,云享云,小摩兽,码上按摩,恒林椅业,INGREM英格瑞玛,头等舱,爽蛙,尚铭电器,东方神,荣康,奥佳华,荣泰健康,豪中豪,乐金健康,康忆安,永禾康,本博,乐尔康,南极人,佳仁,茗振,QTQ,志高,乐摩吧,摩摩哒,爽客,码客街,头等舱互联奇拉,久工实业
中国老年人数量增长、亚健康人群超75.0%,具有养生需求的人群利好按摩椅市场的发展。2018年,中国按摩椅相关企业获投资金额2.6亿元,平均每笔按摩椅投资额超过5000万元。具体到两大电商销售渠道,按摩椅在天猫商城的月销售千笔以上的单品均价为3158.9元,京东商城热销前十的单品均价为6529.8元。在按摩市场细分企业中,2018荣泰健康、奥佳华第一大品类均为按摩椅,其营收占比分别为83.0%、42.2%。在按摩概念的广泛渗透下,共享按摩椅开始出现,目前主要应用场景在电影院、景区、地铁站、写字楼等。
The number of elderly people in China has increased, and the number of sub-healthy people has exceeded 75.0%. People who have health needs are in favor of the development of massage chair market. In 2018, China's massage chair-related enterprises received an investment of 260 million yuan, with an average investment of more than 50 million yuan per massage chair. Specifically to the two major e-commerce sales channels, the average price of massage chairs in Tianmao Mall is 3158.9 yuan per month, while the average price of the top ten items in Jingdong Mall is 6529.8 yuan. In the massage market segment enterprises, Rongtai Health and Ogawa's first major category in 2018 are massage chairs, whose revenue accounts for 83.0% and 42.2% respectively. Under the extensive penetration of massage concept, the sharing massage chair began to appear. At present, the main application scenarios are in cinemas, scenic spots, subway stations, office buildings, etc. -
艾媒报告 |2019年中国生物医药产业发展及舆论焦点分析报告
本报告研究涉及企业/品牌包括:Takeda、GSK、Sanofi、Celgene、Novartis、宝洁、CVC Fund VII、Shire、诺华OTC、Bioverativ、Juno Therapeutics、AveXis、Impact Biomedicines、Tesaro、Ablynx、默克OTC、Recordati控股公司FIMEI、复星医药、海正药业、康弘药业、泰合健康、齐鲁制药、复宏汉霖、信达生物、张江生物、恒瑞医药、三生国健、嘉和生物、百奥泰、深圳龙瑞、天坛生物、华兰生物、博雅生物、上海莱士、卫光生物、辽宁成大、智飞生物、康泰生物、沃森生物、利德曼、交大昂立、华润双鹤、力生制药、海欣股份、联环药业、白云山、中源协和、普洛药业
随着生物医药技术不断突破,中国生物医药产业快速发展,2018年,单抗、血液制品、疫苗等生物医药相关领域多家头部上市企业营收均超亿元,实现同比增长。iiMedia Research(艾媒咨询)监测发现,生物医药产业网络言值指数为49.7,网民评价态度偏向正面,上海网民对生物医药产业的关注度最高。未来,随着中国生物医药行业上市公司数量增多,行业与企业间竞争将更加激烈。
The scale of China's bio-pharmaceutical industry continues to grow, and the proportion of bio-pharmaceutical output in the pharmaceutical industry continues to rise. In 2017, the total output value of the bio-pharmaceutical industry in China's park was about 1.5 trillion yuan. At present, China's biomedical industry has formed three major clusters, including the Bohai Rim region, the Yangtze River Delta region and the Pearl River Delta region, and the industrial agglomeration effect is outstanding. China's bio-pharmaceutical industry is in a stage of rapid development. In 2018, many head-to-head listed companies in biomedical related fields such as monoclonal antibodies, blood products and vaccines all exceeded 100 million yuan, achieving year-on-year growth. According to iiMedia Research, netizens in Shanghai are most concerned about the biomedical industry, and 40.9% of netizens surveyed support the application of transgenic technology in the pharmaceutical field. Among the heads of monoclonal antibodies, blood products and vaccines, Fuhong Hanlin as well as Weiguang Bio and Lidmanthe has the best online reputation,iiMedia Consulting analysts believe that in the future, the combination of artificial intelligence with new drug research and the fierce competition among head enterprises is an important trend in the development of China's biomedical industry.
没找到想要的报告?
扫码添加客服参与预约/定制,第一时间获取行业推荐报告!
智库热榜
艾媒咨询|2024-2025年中国银发经济投资前景分析报告
艾媒咨询|2024-2025年中国烘焙食品行业现状及趋势研究报告
艾媒咨询 | 2023-2024年中国休闲食品产业现状及消费行为数据研究报告
艾媒咨询|2024-2025年全球及中国新能源汽车行业消费趋势监测与案例研究报告
艾媒咨询 | 2023-2024年中国全域旅游产业运行数据及发展趋势研究报告
艾媒咨询 | 2024年中国家用美容仪行业消费者洞察研究报告
艾媒咨询|赵一鸣零食店消费行为洞察及行业趋势报告(2024)
艾媒咨询|2024年中国月饼行业创新发展研究报告
艾媒咨询 | 2024年中国数字中台市场研究报告
艾媒咨询|2023-2024年全球及中国跨境电商运营数据及典型企业分析研究报告
艾媒咨询|2024年中国家清产品消费趋势洞察报告